secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001193125-25-030780
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Pharma discloses 2024 bonuses, 2025 salaries, and RSU grants for NEOs
---------------------------------------------------------------------------

- CEO Polymeropoulos: 2024 bonus $947,928; 2025 base salary $965,655; target bonus 80%; 450,000 RSUs.
- CFO Moran and three SVPs: 2024 bonuses $309,181–$320,040; 2025 base $559,935–$579,600; 45% target; 125,000 RSUs each.
- All RSUs vest in four equal annual installments commencing March 1, 2026.
- Compensation Committee considered peer-group analysis by Willis Towers Watson before approving.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312525030780/0001193125-25-030780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312525030780/d935984d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-030780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer